Results of biopsy-proven sellar germ cell tumors: nine years' experience in a single center.

Results of biopsy-proven sellar germ cell tumors: nine years' experience in a single center.

World Neurosurg. 2018 Jan 08;:

Authors: Zhang Y, Zhu H, Deng K, Ma W, Wang Y, Sun J, Lian X, Pan H, Wang R, Yao Y

Abstract
BACKGROUND: The biopsy is recognized as the most accurate method to determine the histological characterization of sellar germ cell tumors. It is very difficult to evaluate the prognosis before histological confirmation.
OBJECTIVES: This study aimed to evaluate the independent prognostic risk factors of patients with sellar germ cell tumors (GCTs).
METHODS: From January 2008 to December 2015, 61 patients who were histologically diagnosed as sellar GCTs did follow-ups and were included in this retrospective study.
RESULTS: Of 61 patients in this study, 40 (65.6%), 10 (16.4%), 11 (18.0%) were diagnosed as pure germinomas, germinomas with syncytiotrophoblastic giant cells (STGC) and non-germinomatous germ-cell tumors (NGGCT), respectively. The patients with pure germinomas had a significantly better overall survival time than those with NGGCT (56.47 ± 3.01 months vs 43.09 ± 10.58 months, p = 0.01). Multivariate analysis demonstrated the independent poor prognostic risk factors of patients with sellar GCTs were the most diameters more than 15mm (OR 7.40; 95% CI 2.01-27.19), OCT positive (OR 5.97; 95% CI 1.40-25.48) and NGGCT (OR 11.88; 95% CI 2.37-59.50), while the combination of chemotherapy and radiotherapy (RT) was associated with a better prognosis (OR 0.15; 95% CI 0.04-0.55).
CONCLUSIONS: The most diameters more than 15mm, OCT positive or NGGCT, was associated with a poorer prognosis for patients with sellar GCTs, while the combination of chemotherapy and RT was associated with a better prognosis.

PMID: 29325960 [PubMed - as supplied by publisher]

http://ift.tt/2Fwy3K2